Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Immunosuppression-Associated B-Cell Lymphoproliferative Disorders
NCT00003716Phase 2Completed
- Sponsor
- Stanford University
- Start
- Mar 1998
- Primary completion
- Jan 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in B-cell lymphoproliferative disorders (B-LPD), sponsored by Stanford University. Started Mar 1998; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell lymphoproliferative disorders (B-LPD)
Beyond the preview
Go deeper on NCT00003716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003716.